CLINICAL TRIALS PROFILE FOR UROXATRAL
✉ Email this page to a colleague
All Clinical Trials for UROXATRAL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00103402 ↗ | Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome | Completed | University of Pennsylvania | Phase 3 | 2005-02-01 | The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Alfuzosin is a once daily (10 mg capsule), FDA approved medication for an indication in benign prostatic hyperplasia (BPH). The effectiveness of alfuzosin in improving lower urinary tract symptoms in patients with BPH has been documented in a number of placebo-controlled studies. A number of small studies have also suggested that alfuzosin ameliorates CP/CPPS symptoms through a similar alpha-blockade mechanism. This study will enable further testing of this hypothesis |
| NCT00103402 ↗ | Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 3 | 2005-02-01 | The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Alfuzosin is a once daily (10 mg capsule), FDA approved medication for an indication in benign prostatic hyperplasia (BPH). The effectiveness of alfuzosin in improving lower urinary tract symptoms in patients with BPH has been documented in a number of placebo-controlled studies. A number of small studies have also suggested that alfuzosin ameliorates CP/CPPS symptoms through a similar alpha-blockade mechanism. This study will enable further testing of this hypothesis |
| NCT00256399 ↗ | Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) | Unknown status | Sanofi | N/A | 2005-11-01 | Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED. |
| NCT00256399 ↗ | Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) | Unknown status | University Hospitals Cleveland Medical Center | N/A | 2005-11-01 | Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED. |
| NCT01418586 ↗ | Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fasted Conditions | Completed | Torrent Pharmaceuticals Limited | Phase 1 | 1969-12-31 | Objective: Primary objective of the present study was to assess the relative bioavailability of two formulations of Extended Release Alfuzosin 10 mg under Fasted conditions, in healthy adult male subjects after an oral administration with 7 days washout period. Study Design: Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence Study |
| NCT01418599 ↗ | Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed Conditions | Completed | Torrent Pharmaceuticals Limited | Phase 1 | 1969-12-31 | Objective: Primary objective of the present study was to assess the relative bioavailability of two formulations of Extended Release Alfuzosin 10 mg under Fed conditions, in healthy adult male subjects after an oral administration with 7 days washout period. Study Design: Open-Label, Randomised, two Period, two treatment, Crossover, Single-Dose Bioequivalence Study |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for UROXATRAL
Condition Name
Clinical Trial Locations for UROXATRAL
Trials by Country
Clinical Trial Progress for UROXATRAL
Clinical Trial Phase
Clinical Trial Sponsors for UROXATRAL
Sponsor Name
